Arctic Vision collects $100M to bring US eye disease candidates overseas
With three eye disease candidates, in-licensed from the US, Shanghai-based Arctic Vision has hooked more than $100 million to see the therapies to the Chinese market — and possibly beyond, if CEO Eddy Wu gets his way.
Wu took the wraps off a Series B round Wednesday evening, just several months after unveiling a $32 million A round. The new funds will be used to develop three candidates licensed from Clearside Biomedical and Eyenovia (one of which was slapped with a CRL back in 2019), and extend the company’s reach to other parts of Asia, he said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.